BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues [Yahoo! Finance]
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]